Tumour marker for the early detection and therapy of HPV-induced anal cancer for HIV+ patients

Tumour marker for the early detection and therapy of HPV-induced anal cancer for HIV+ patients

A pilot study has compared serum samples of HIV+ patients before and after treatment of an HPV induced anal carcinoma using the Prevo-Check®.

Prevo-Check® has been confirmed as a high quality test for the early detection and therapy of HPV induced anal cancer for HIV+ patients. Study participants showing a high Prevo-Check® result developed anal cancer within one year.

Read more on background, methodology and results of the study. Note: This abstract is available in German only please contact Abviris direct for assistance in English.

 

study tumour marker HIV patients

Leave a reply

Your email address will not be published. Required fields are marked *

four × one =